Get started
Author

Kohei Aoe

Survival and Prognostic Factors in Malignant Pleural Mesothelioma: A Retrospective Study of 314 patients in the West Part of Japan
2010 · S. Nojiri, K. Gemba, et al. · Japanese Journal of Clinical Oncology · 69
Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma
2014 · J Yamamoto, K Ohnuma, et al. · British Journal of Cancer · 28
PDF
Interstitial lung disease (ILD) during gefitinib treatment in Japanese patients with non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group
2004 · K. Hotta, S. Harita, et al. · Journal of Clinical Oncology · 19
Effects of short-term pulmonary rehabilitation on exercise capacity and quality of life in patients with chronic obstructive pulmonary disease.
2000 · N Miyahara, R Eda, et al. · PubMed · 19
MA 19.01 A Phase II Study of Nivolumab: A Multicenter, Open-Label, Single Arm Study in Malignant Pleural Mesothelioma (MERIT)
2017 · Y. Goto, M. Okada, et al. · Journal of Thoracic Oncology · 16
Association of immunoglobulin G4 and free light chain with idiopathic pleural effusion
2017 · Y Murata, K Aoe, et al. · Clinical & Experimental Immunology · 14
PDF
Prognostic significance of proliferating cell nuclear antigen (PCNA) expression in non-small cell lung cancer.
1993 · M Fujii, M Motoi, et al. · PubMed · 14
PDF
OA08.01 Long-Term Efficacy and Safety of Nivolumab in Second- or Third-Line Japanese Malignant Pleural Mesothelioma Patients (Phase II: MERIT Study)
2018 · T. Nakano, M. Okada, et al. · Journal of Thoracic Oncology · 7
Establishment of a drug sensitivity panel using human lung cancer cell lines.
1999 · A Matsushita, M Tabata, et al. · PubMed · 7
PDF
The first nationwide survival analysis of Japanese mesothelioma patients from Vital Statistics of Japan.
2010 · K. Aoe, A. Hiraki, et al. · Journal of Clinical Oncology · 6
1895MO Three-year follow-up results of the MERIT trial: A Japanese phase II study of nivolumab in malignant pleural mesothelioma
2020 · H. Hayashi, M. Okada, et al. · Annals of Oncology · 3
Merlin Immunohistochemistry Is Useful in the Differential Diagnosis of Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia
2025 · Kohei Aoe, Kei Kushitani, et al. · Pathology International · 2
3072 Phase 2: Docetaxel with or without ramucirumab as therapy for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations after prior EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy
2015 · K. Kasahara, K. Kiura, et al. · European Journal of Cancer · 2
1898P A phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma: JME-001
2020 · N. Fujimoto, T. Kozuki, et al. · Annals of Oncology · 1
Updated analysis of a phase I trial of afatinib (Afa) and bevacizumab (Bev) in chemo-naïve patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring EGFR-mutations: OLCSG1404
2019 · T. Ninomiya, N. Nogami, et al. · Annals of Oncology · 1
PDF
A large prospective cohort study of the clinical features of advanced lung cancer harboring HER2 aberrations (HER2-CS STUDY)
2017 · T. Tanaka, H. Yoshioka, et al. · Annals of Oncology · 1
PDF
A Phase Ii Trial of Gefitinib in Combination with Bevacizumab As First-Line Therapy for Advanced Non-Small-Cell Lung Cancer with Activating Egfr Gene Mutations: Olcsg 1001
2014 · N. Nogami, E. Ichihara, et al. · Annals of Oncology · 1
Evidence against a role for simian virus 40 in malignant mesothelioma in Japan
2006 · A. Hiraki, K. Aoe, et al. · Journal of Clinical Oncology · 1
[Orchiectomy for tuberculous epididymitis: a report of two cases with intractable to antituberculosis treatment].
2001 · N Kunichika, K Murakami, et al. · PubMed · 1
Reply to “Correspondence: SPARC, HEG1, and the Diagnosis of Epithelioid Mesothelioma” by Churg et al
2024 · Tetsuya Nakagiri, Vishwa J. Amatya, et al. · The American Journal of Surgical Pathology
Fatal myocardial infarction investigated using contrast‐enhanced postmortem computed tomography: A case report
2023 · Kohei Aoe, Yuichi Orita, et al. · Clinical Case Reports
PDF
P1.01-47 Prospective Study for Usefulness of Plasma DNA on Prediction of Third Generation EGFR Tyrosine Kinase Inhibitors (S-PLAT Study)
2019 · C. Nakashima, H. Yoshida, et al. · Journal of Thoracic Oncology
PDF
P2.06-10 Combination Chemotherapy with Cisplatin, Pemetrexed, and Nivolumab for Malignant Pleural Mesothelioma: A Trial in Progress
2018 · N. Fujimoto, K. Aoe, et al. · Journal of Thoracic Oncology
PDF
P1.03-038 A Phase I Trial of Afatinib and Bevacizumab in Untreated Patients with Advanced NSCLC Harboring EGFR-Mutations: OLCSG1404
2017 · S. Kuyama, K. Kudo, et al. · Journal of Thoracic Oncology
OA 12.03 Clinical Features of Advanced Lung Cancer Harboring HER2 Aberrations: A Large Prospective Cohort Study (HER2-CS STUDY)
2017 · S. Hosokawa, A. Bessho, et al. · Journal of Thoracic Oncology
PDF
Works count: 34
Citation count: 212
H-index: 7
I10-index: 7
Year
Topic
Type